Disc Medicine IRON Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense by Product | ||||||
| Bitopertin | $9.34M+10.7% | $14.87M+102% | $11.83M+63.0% | $23.69M+233% | $8.44M+32.4% | |
| DISC Three Four Zero Five | $9.19M+451% | $2.21M+4.5% | $11.91M+266% | $1.91M-50.7% | $1.67M-64.5% | |
| DISC Zero Nine Seven Four | $8.11M+32.5% | $9.48M+125% | $7.37M+29.9% | $4.62M+40.3% | $6.12M+62.3% | |
| Internal Research And Development | $11.31M+67.6% | $10.35M+47.8% | $10.7M+91.6% | $9.15M+57.9% | $6.75M+25.0% | |
| Other Research | $2.17M+18.2% | $4.57M+130% | $4.1M+232% | $3.1M+60.1% | $1.83M+6.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Disc Medicine break its business down?
- Disc Medicine (IRON) reports research and development expense by product across 5 parts — Bitopertin, DISC Three Four Zero Five, DISC Zero Nine Seven Four, Internal Research And Development and Other Research. Each is extracted from the segment footnotes and tracked over time.
- Where does Disc Medicine's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Disc Medicine's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.